Serum amyloid A protein (SAA) in colorectal carcinoma

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 2, 2001, Pages 129-133

  Glojnaric I ^a   Casl M T ^a   Simic D ^a   Lukac J H ^a   Fujita, S ^a   Kakizoe, T ^a  

^a Research and Development   (Croatia)

Author keywords

Acute phase reaction; Colorectal carcinoma; ELISA; Serum amyloid A protein; Tumour marker

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; C REACTIVE PROTEIN; OROSOMUCOID; SERUM AMYLOID A; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETER; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; SENSITIVITY AND SPECIFICITY; STATISTICS;

ALPHA 1-ANTICHYMOTRYPSIN; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; HUMANS; OROSOMUCOID; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0035044124     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.022     Document Type: Article

References (37)

1. Acute phase reactant proteins as prognostic indicators in cancer
2. Acute phase proteins and recombinant IL-2 therapy: Prediction of response and survival in patients with colorectal cancer
3. Serum amyloid A (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis
4. Acute phase reactants in inflammation and infection
5. Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice
6. Serum amyloid A protein in the prediction of postburn complications and fatal outcome in patients with severe burns
7. The diagnostic capacity of serum amyloid A protein for early recognition of kidney allograft rejection
8. 1-acid glycoprotein and fibrinogen
9. The value of acute phase protein measurements in clinical practice
10. Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient
11. Serum amyloid A (SAA): A concise review of biology, assay methods and clinical usefulness
12. Inflammation, the acute phase response and atherosclerosis
13. C-reactive protein: Structural biology and host defence function
14. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties
15. Parathyroid hormone-related protein is induced in the adult liver during endotoxemia and stimulates the hepatic acute phase response
16. Detection of serum amyloid A protein in very low density and high density lipoproteins of patients after acute myocardial infarction
17. Association between serum amyloid A proteins and coronary artery disease
18. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse
19. Colorectal cancer staging-an overview
20. A rapid enzyme-linked immunosorbent assay (ELISA) for quantitative determination of serum amyloid A (SAA) using sequence-specific antibody
21. Production of an amino acid sequence-specific antiserum against human amyloid A (AA) and serum amyloid A (SAA) protein
22. Immunochemical quantitation of antigens by single radial immunodiffusion
23. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits
24. Serum Amyloid A to monitor Cancer Dissemination
25. Acute phase proteins or tumour markers: The role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases
26. The differential diagnostic capacity of serum amyloid A protein between infectious and non-infectious febrile episodes of neutropenic patients with acute leukaemia
27. Serum amiloyd A in Carcinoma of the lung
28. Urinary zinc excretion and acute phase response in cancer patients
29. The acute phase protein response in patients receiving subcutaneous IL-6
30. Serum levels of interleukin 6 in patients with lung cancer
31. Serum amyloid A protein in patients with acute myocardial infarction
32. Clinical relevance of serum amyloid A protein monitoring in urinary tract infections
33. The diagnostic capacity of serum amyloid A protein for early recognition of kidney allograft rejection
34. Serum carcinoembryonic antigen and acute phase reactant proteins in the preoperative detection of fixation of colorectal tumours
35. Biochemical markers in gastrointestinal malignancies
36. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease